2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. CDK

CDK

Cyclin dependent kinase

CDK

Related Products

PDF 1.19 MB

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

CDK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-150213A
    ODN BW001 sodium
    		Inhibitor
    ODN BW001 sodium is an oligodeoxynucleotide (ODN). ODN BW001 sodium plays a regulatory role in the proliferation and activation of osteoblast.
    ODN BW001 sodium
  • HY-161857
    Akt/mTOR-IN-1
    		Activator
    Akt/mTOR-IN-1 (Compound 8r) is an AKT/mTOR signaling pathway inhibitor exhibiting an IC50 value of 0.8 µM with anticancer activity. Akt/mTOR-IN-1 can decrease the expression of Caspase 3 and increase the expression of the autophagic protein Cyclin B1, thereby inducing cell autophagy and apoptosis. Akt/mTOR-IN-1 can be used in research related to non-small cell lung cancer (NSCLC).
    Akt/mTOR-IN-1
  • HY-E70658
    CDK12 R722C/CycK Recombinant Human Active Protein Kinase
    CDK12 R722C/CycK Recombinant Human Active Protein Kinase is a cyclin-dependent kinase and regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability.
    CDK12 R722C/CycK Recombinant Human Active Protein Kinase
  • HY-172807
    p38α-IN-9
    		Inhibitor
    p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α-IN-9 inhibits MK2T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis.
    p38α-IN-9
  • HY-117988
    SNX2-1-108
    		Inhibitor
    SNX2-1-108 is a CDK8 kinase inhibitor.
    SNX2-1-108
  • HY-RS02352
    CDK11A Human Pre-designed siRNA Set A

    CDK11A Human Pre-designed siRNA Set A contains three designed siRNAs for CDK11A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    CDK11A siRNA-1: 5 nmol (HPLC)

    CDK11A siRNA-2: 5 nmol (HPLC)

    CDK11A siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)
    CDK11A Human Pre-designed siRNA Set A
  • HY-137478B
    KB-0742 hydrochloride
    		Inhibitor
    KB-0742 hydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 hydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 hydrochloride has potent anti-tumor activity.
    KB-0742 hydrochloride
  • HY-161690
    EF-4-177
    		Inhibitor
    EF-4-177 is an orally active and allosteric CDK2 inhibitor with the IC50 of 87 nM. EF-4-177 can disrupt spermatogenesis.
    EF-4-177
  • HY-145389
    SZ-015268
    		Inhibitor
    SZ-015268 is a CDK7 inhibitor with an IC50 of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC50s of 33, 80.56, 12.53, and 61.55 nM, respectively.
    SZ-015268
  • HY-149963
    PROTAC CDK9 degrader-6
    		Inhibitor
    PROTAC CDK9 degrader-6 is a PROTAC targeting to CDK9 sepcifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC50s of 0.10 μM and 0.14 μM for the CDK942 and CDK955 isoforms, respectively.
    PROTAC CDK9 degrader-6
  • HY-E70676
    CDK20/CycT1 Recombinant Human Active Protein Kinase
    CDK20 is a major controller of cell cycle checkpoints, which regulate cell growth and proliferation and perform a role in the development of many malignancies. CDK20 is thought to have Cyclin-dependent activating kinase (CAK) activity for CDK2 when it is complexed with Cyclin H. CDK20/CycT1 Recombinant Human Active Protein Kinase is an ortholog of CDK20.
    CDK20/CycT1 Recombinant Human Active Protein Kinase
  • HY-RS02360
    Cdk13 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Cdk13 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk13 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Cdk13 Mouse Pre-designed siRNA Set A
  • HY-178756
    CDK2-IN-48
    		Inhibitor
    CDK2-IN-48 (Compound 109) is a CDK2 inhibitor and can be used for the study of CDK2-dependent cancers.
    CDK2-IN-48
  • HY-153718
    KI-ARv-03
    		Inhibitor
    KI-ARv-03 is a potent and selective ATP-competitive CDK9 inhibitor with an IC₅₀ of 0.15 μM (at 45 μM ATP), exhibiting over 130-fold selectivity against other CDKs (including CDK1-7). KI-ARv-03 reduces androgen receptor (AR)-driven transcription and proliferation in prostate cancer cells. KI-ARv-03 can be used for leukemia, pancreatic cancer, alveolar rhabdomyosarcoma (ARMS) and castration-resistant prostate cancer (CRPC) research. KI-ARv-03 is a ligand for target protein for PROTAC. KI-ARv-03 can be used to synthesize PROTAC KI-CDK9d-32 (HY-173523)[1][2].
    KI-ARv-03
  • HY-173510
    CLK2/3-IN-1
    		Inhibitor
    CLK2/3-IN-1 (Compound 7c) is an orally active CLK2/3 inhibitor (EC50: 5.07 nM and 30.03 nM, respectively). CLK2/3-IN-1 binds to Lys193 and Lys186 of CLK2/3 via hydrogen bonds. CLK2/3-IN-1 can inhibit the proliferation of SW480 tumor cells (IC50: 163 nM). CLK2/3-IN-1 can be used to study CLK-related tumor diseases.
    CLK2/3-IN-1
  • HY-E70654
    CDK1/CycE1 Recombinant Human Active Protein Kinase
    CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK1.
    CDK1/CycE1 Recombinant Human Active Protein Kinase
  • HY-156795
    PROTAC CDK9/CycT1 Degrader-2
    		Inhibitor
    PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of CDK9, with the IC50 of 45 nM.
    PROTAC CDK9/CycT1 Degrader-2
  • HY-161978
    CDK4/6-IN-22
    		Inhibitor
    CDK4/6-IN-22 (Compound 1-A) is a CDK4 and CDK6 dual inhibitor.
    CDK4/6-IN-22
  • HY-178168
    ARUK2010694
    		Inhibitor
    ARUK2010694 (Compound 20) is a potent and selective NUAK1 inhibitor with a pIC50 of 8.7. ARUK2010694 also inhibits CDK2, CDK4 and CDK6 activity, with inhibitory rate of 13%, 63% and 32% at 1 μM. ARUK2010694 can be used for the research of neurological disease, such as Alzheimer’s disease (AD).
    ARUK2010694
  • HY-161768
    VCC972839:01
    		Inhibitor
    VCC972839:01 is an inhibitor for cyclin dependent kinase (CDK9), with IC50 of 7 nM. VCC972839:01 inhibits the cell viability of SCLC cells in nanomolar levels. VCC972839:01 induces apoptosis through an intrinsic pathway. VCC972839:01 exhibits antitumor activity in mouse model.
    VCC972839:01
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
CDK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.